Plasma concentration of C-reactive protein is increased in Type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: Evidence for chronic inflammation

Diabetologia

Volumn 42, Issue 3, 1999, Pages 351-357

  Schalkwijk, C G ^a,b   Poland, D C W ^b   Van Dijk, W ^b   Kok, A ^a   Emeis, J J ^d   Drager A M ^a   Doni, A ^c   Van Hinsbergh, V W M ^b,d   Stehouwer, C D A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d TNO   (Netherlands)

Author keywords

1 Acid glycoprotein; Acute phase response; Atherosclerosis; C reactive protein; Fucosylation; Inflammation; Type I (insulin dependent) diabetes mellitus; Vascular disease

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; OROSOMUCOID; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENDOTHELIUM INJURY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; MALE; OROSOMUCOID; PHOSPHOLIPASES A; REFERENCE VALUES; REGRESSION ANALYSIS; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR;

EID: 0033030238     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051162     Document Type: Article

References (33)

1. 1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038
2. 2. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809
3. 3. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MM (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349: 426-466
4. 4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979
5. 5. Pickup JC, Mattock, MB, Chusney, GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292
6. 6. McMillan DE (1979) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042-1046
7. 7. Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J (1996) Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Throm Res 81: 485-490
8. 1-protease inhibitor in severely burned patients: relation to interleukin-6 levels. Clin Exp Immunol 82: 579-582
9. 1-acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosus. Arthritis Rheum 30: 513-518
10. 1-acid glycoprotein in the serum of rheumatoid arthritis patients: A longitudinal study. J Rheumatol 21: 2209-2216
11. 1-acid glycoprotein (orosomucoid) in human sera. J Exp Med 177: 657-666
12. 1-Acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Adv Exp Med Biol 435: 145-150
13. 1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurance of di-, tri-, and tetraantennary glycans and the degree of sialylation. Eur J Biochem 175: 387-394
14. 14. Hamsten A (1995) Hemostatic function and coronary artery disease. N Engl J Med 332: 677-678
15. 15. Stehouwer CDA, Lambert J, Donker AJM, Van Hinsbergh VWM (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34: 55-68
16. 16. Highton J, Hessian PA (1984) A solid-phase enzyme immunoassay for C-reactive protein: clinical value an the effect of rheumatoid factor. J Immunol Methods 68: 185-192
17. 2. Cancer Immunol Immunother 41: 287-292
18. 18. Bottazzi B, Vouret-Craviari V, Bastone A et al. (1997) Multimer formation and ligand recognition by the long pentraxin PTX3: similarities and differences with the short pentraxins C reactive proteins and serum amyloid P component. J Biol Chem 272: 32817-32829
19. 19. Introna M, Alles VV, Castellano M et al. (1996) Cloning of mouse pt x 3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 87: 1862-1872
20. 20. Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43: 52-58
21. 21. Vighushin DM, Pepys MB, Hawkins PN (1993) Metabolic and scintigraphic studies of radiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351-1357
22. 22. Wiese TJ, Dunlap JA, Yorek MA (1997) Effect of L-fucose and D-glucose concentration on L-fucoprotein metabolism in human Hep G2 cells and changes in fucosyltransferase and α-L-fucosidase activity in liver of diabetic rats. Biochim Biophys Acta 1335: 61-72
23. 23. Ronquist G, Walinder O (1983) Increased activity of serum fucosyltransferase in diabetic patients. Diabete Metabolisme 9: 212-216
24. 24. Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: Biochemical, biological and clinical implications for diabetes and aging. Lab Invest 70: 138-151
25. 25. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H (1990) Advanced protein glycation induces transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87: 9010-9014
26. 26. Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 268: 9889-9897
27. 27. Vlassara H, Brownlee M, Manogue HR, Dinarello C, Pasagian A (1988) Cachetin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodeling. Science 240: 1546-1548
28. 28. Schmidt AM, Hasu M, Popov M et al. (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interaction and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91: 8807-8811
29. 29. Hotamisligil GS, Arner, P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin restistance. J Clin Invest 95: 2409-2415
30. 30. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes mellitus. N Eng J Med 310: 356-360
31. 31. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 31: 219-226
32. 32. Messent JWC, Elliot TG, Hill RD, Jarrett RJ, Keen H, Viberti GC (1992) Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus; a 23-year follow up study. Kidney Int 41: 836-839
33. 33. Stehouwer CDA, Fischer HRA, Van Kuijk AWR, Polak BCP, Donker AJM (1995) Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 444: 561-564